Evidence map›Paper›PMID 39629162›Full record

ReviewEngineering microbiology2021

Integrated engineering of enzymes and microorganisms for improving the efficiency of industrial lignocellulose deconstruction.

Guodong Liu, Yinbo Qu

Abstract readReview
In one paragraph

Review in Engineering microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Engineering ofEngineering microbiology · 2023
    Review
  15. Characterization of a New Glucose-Tolerant GH1 β-Glycosidase fromInternational journal of molecular sciences · 2023
    Article
  16. Article
  17. Strain improvement ofFrontiers in microbiology · 2023
    Review
  18. Plastid Transformation: New Challenges in the Circular Economy Era.International journal of molecular sciences · 2022
    Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Guodong LiuState Key Laboratory of Microbial Technology, Shandong University, Qingdao 266237, China.
Yinbo QuState Key Laboratory of Microbial Technology, Shandong University, Qingdao 266237, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bioconversion of lignocellulosic biomass to fuels and chemicals represents a new manufacturing paradigm that can help address society's energy, resource, and environmental problems. However, the low efficiency and high cost of lignocellulolytic enzymes currently used hinder their use in the industrial deconstruction of lignocellulose. To overcome these challenges, research efforts have focused on engineering the properties, synergy, and production of lignocellulolytic enzymes. First, lignocellulolytic enzymes' catalytic efficiency, stability, and tolerance to inhibitory compounds have been improved through enzyme mining and engineering. Second, synergistic actions between different enzyme components have been strengthened to construct customized enzyme cocktails for the degradation of specific lignocellulosic substrates. Third, biological processes for protein synthesis and cell morphogenesis in microorganisms have been engineered to achieve a high level and low-cost production of lignocellulolytic enzymes. In this review, the relevant progresses and challenges in these fields are summarized. Integrated engineering is proposed to be essential to achieve cost-effective enzymatic deconstruction of lignocellulose in the future.

Indexed as

BiorefineryCellulaseFungiGenetic engineeringHemicellulaseLignocellulose

Identifiers

PMID39629162
PMCPMC11610957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.